Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.

Nieto Y, Aldaz A, Rifón J, Pérez-Calvo J, Zafra A, Zufia L, Viúdez A, Viteri S, Aramendía JM, Aristu J, Centeno C, Moreno M, Sayar O, Hernández M.

Biol Blood Marrow Transplant. 2007 Nov;13(11):1324-37. Epub 2007 Sep 7.

2.

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.

Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Barón AE, Jones RB.

Biol Blood Marrow Transplant. 2005 Apr;11(4):297-306.

3.

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.

Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA.

Cancer Chemother Pharmacol. 2001 Aug;48(2):95-103.

PMID:
11561784
4.

Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.

Tassinari D, Drudi G, Panzini I, Pasini G, Arcangeli V, Fochessati F, Gianni L, Mianulli AM, Oliverio G, Pasquini E, Sartori S, Ravaioli A.

Int J Clin Oncol. 2001 Dec;6(6):279-83.

PMID:
11828946
5.

Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.

Soo RA, Lim HL, Wang LZ, Lee HS, Millward MJ, Tok LT, Lee SC, Lehnert M, Goh BC.

Cancer Chemother Pharmacol. 2003 Aug;52(2):153-8. Epub 2003 May 16.

PMID:
12750842
6.

A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.

Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Celebi H, Ustün C, Akan H, Demirer S, Aydintuğ S, Uysal A, Koç H.

Bone Marrow Transplant. 2000 Apr;25(7):697-703.

7.

Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.

Thomas P, Robinet G, Ferri-Dessens RM, Léna H, Gouva S, Vernejoux JM, Kleisbauer JP.

Lung Cancer. 2002 May;36(2):191-8.

PMID:
11955654
8.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH.

Gynecol Oncol. 2013 Sep;130(3):511-7. doi: 10.1016/j.ygyno.2013.05.001. Epub 2013 May 9.

PMID:
23665458
9.

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.

Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E 3rd, Ayash L.

Bone Marrow Transplant. 2001 Feb;27(3):269-78.

10.

Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.

Gajra A, Mehdi SA, Kirshner J, Newman N, Graziano SL.

Lung Cancer. 2001 May;32(2):189-96.

PMID:
11325490
11.

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM.

J Clin Oncol. 2006 Jan 20;24(3):500-6.

PMID:
16421427
12.

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

Rebattu P, Quantin X, Ardiet C, Morere JF, Azarian MR, Schuller-Lebeau MP, Pujol JL.

Lung Cancer. 2001 Aug-Sep;33(2-3):277-87.

PMID:
11551423
13.

Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.

Oka M, Fukuda M, Nagashima S, Fukuda M, Kinoshita A, Soda H, Doi S, Narasaki F, Suenaga M, Takatani H, Nakamura Y, Kawabata S, Tsurutani J, Kanda T, Kohno S.

Cancer Chemother Pharmacol. 2001 Dec;48(6):446-50.

PMID:
11800024
14.

A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.

Carmichael J, Allerheiligen S, Walling J.

Semin Oncol. 1996 Oct;23(5 Suppl 10):55-9.

PMID:
8893883
15.

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.

Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S.

Oncology. 2005;68(4-6):382-90. Epub 2005 Jul 12. Review.

PMID:
16020967
16.
17.

Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.

Wang LR, Huang MZ, Zhang GB, Xu N, Wu XH.

Cancer Chemother Pharmacol. 2007 Sep;60(4):601-7. Epub 2007 Jun 5.

PMID:
17549479
18.

Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.

Dudek AZ, Larson T, Keshtgarpour M, Kumar P.

Am J Clin Oncol. 2007 Oct;30(5):481-6.

PMID:
17921707
19.
20.

A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.

Weaver CH, Greco FA, Hainsworth JD, Zhen B, Baldwin P, Wittlin F, Lewis M, West WH, Schwartzberg L, Buckner CD.

Bone Marrow Transplant. 1997 Nov;20(10):847-53.

Supplemental Content

Support Center